Overview
Primary congenital hypothyroidism (CH) is a condition present at birth in which the thyroid gland fails to produce adequate amounts of thyroid hormones, most commonly thyroxine (T4) and triiodothyronine (T3). It is one of the most common preventable causes of intellectual disability worldwide. The condition may result from thyroid dysgenesis (absent, ectopic, or hypoplastic thyroid gland), which accounts for approximately 80-85% of cases, or from thyroid dyshormonogenesis (defects in thyroid hormone synthesis), which accounts for most of the remaining cases. In rare instances, it can also be caused by defects in TSH receptor signaling. Thyroid hormones are essential for normal growth and neurodevelopment, particularly during the first years of life. Without early detection and treatment, affected infants may develop severe and irreversible intellectual disability, growth failure, and neurological impairment. In the neonatal period, symptoms can be subtle but may include prolonged jaundice, feeding difficulties, constipation, a large fontanelle, hypotonia (decreased muscle tone), macroglossia (enlarged tongue), umbilical hernia, dry skin, hoarse cry, and lethargy. Many affected newborns appear clinically normal at birth, which underscores the critical importance of newborn screening programs. Newborn screening for congenital hypothyroidism, now implemented in most developed countries, allows early diagnosis typically within the first two weeks of life. Treatment consists of lifelong thyroid hormone replacement therapy with levothyroxine (synthetic T4), which should be initiated as soon as possible after diagnosis — ideally within the first two weeks of life. With prompt and adequate treatment, children with primary congenital hypothyroidism can achieve normal or near-normal cognitive development and growth. Regular monitoring of thyroid function tests is essential to ensure appropriate dosing throughout childhood and into adulthood.
Variable
Can be inherited in different ways depending on the underlying gene
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Primary congenital hypothyroidism.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Primary congenital hypothyroidism at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Primary congenital hypothyroidism.
Community
No community posts yet. Be the first to share your experience with Primary congenital hypothyroidism.
Start the conversation →Latest news about Primary congenital hypothyroidism
No recent news articles for Primary congenital hypothyroidism.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Primary congenital hypothyroidism
What is Primary congenital hypothyroidism?
Primary congenital hypothyroidism (CH) is a condition present at birth in which the thyroid gland fails to produce adequate amounts of thyroid hormones, most commonly thyroxine (T4) and triiodothyronine (T3). It is one of the most common preventable causes of intellectual disability worldwide. The condition may result from thyroid dysgenesis (absent, ectopic, or hypoplastic thyroid gland), which accounts for approximately 80-85% of cases, or from thyroid dyshormonogenesis (defects in thyroid hormone synthesis), which accounts for most of the remaining cases. In rare instances, it can also be c
At what age does Primary congenital hypothyroidism typically begin?
Typical onset of Primary congenital hypothyroidism is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Primary congenital hypothyroidism?
17 specialists and care centers treating Primary congenital hypothyroidism are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.